Clinical Trial Update: Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

View source ↗

Summary

Clinical trial update indicates that Alnylam's patisiran-LNP pregnancy surveillance program is currently recruiting participants for hereditary transthyretin-me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis

Drugs mentioned

• Onpattro (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy | Status: RECRUITING